Chemistry:Insulin glulisine

From HandWiki
Short description: Rapid-acting insulin analogue
Insulin glulisine
Insulin glulisine 6GV0 cartoon.png
PDB: 6gv0
Clinical data
Trade namesApidra, Apidra SoloStar
AHFS/Drugs.comMonograph
MedlinePlusa607033
License data
Pregnancy
category
  • AU: B3[1]
  • US: C (Risk not ruled out)[1]
Routes of
administration
Subcutaneous, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC258H384N64O78S6
Molar mass5822.64 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[4] It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004;[5] it is sold under the trade name Apidra.[6] When injected subcutaneously, it appears in the blood earlier than human insulin.[7] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[8] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[2]

The most common side effects include hypoglycaemia (low blood glucose levels).[3]

Medical uses

Insulin glulisine is indicated for the treatment of diabetes mellitus.[3][2]

References

External links